Slovakia – Antineoplastic and immunomodulating agents – Lieky ATC skupiny L04AB02, Infliximab parent. 100 mg

Všeobecná zdravotná poisťovňa, a.s.Bratislava - mestská časť Petržalka, SlovakiaEUR 2,667,150 / ~EUR 2,667,15011 days leftopen

Registrieren zum Speichern Documents (1)

Opportunity Score

Confidence: 50%

Complexity: low

11 days

Deadline

supplies

Contract

SME suitableFramework

Deep Portfolio Analysis

Company fit score
Missing certificates
Eligibility blockers
Bid / No-Bid recommendation

Create account for AI analysis

AI Analysis Summary

Moderate opportunity

This tender by Všeobecná zdravotná poisťovňa, a.s. (Slovak health insurance company) is an open procedure for a framework agreement to supply Infliximab 100 mg (ATC L04AB02) over 36 months. The estimated total value is €2,667,150. Award is based on lowest price only. Submission is electronic, required in Slovak language, and the deadline is 30 June 2026.

Strengths

Documents available

Open procedure

Low complexity

Risks

Submission deadline in 11 days

Analysis may be incomplete

Only part of the procurement documentation was analyzed. Additional eligibility requirements, certificates, or submission documents may exist in the remaining tender documentation.

Key Requirements

Open procedure.
Electronic submission required.
Submission languages: Slovak (primary); Czech is listed for a second incomplete lot entry, but likely only Slovak required.

Award Criteria

Najnižšia cena

Type: Price

Criterion

Type

Najnižšia cena

Price

Buyer

Name

Všeobecná zdravotná poisťovňa, a.s.

Location

Bratislava - mestská časť Petržalka, SVK

[email protected]

Buyer profile

Open profile

Identifier

35937874

Lots (1)

#LOT-0001Lieky ATC skupiny L04AB02, Infliximab parent. 100 mg

Supply of Infliximab 100 mg (antineoplastic/immunomodulating agent). Framework agreement for 36 months. Estimated value €2,667,150. Award criteria: lowest price.

EUR 2,667,15033652000SVK